Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Impact of Nutritional Managment on Pregnancy With IBD Patients and Their Springs (IBD/pregnancy)

5 de mayo de 2026 actualizado por: Amira Mohammed Abdel Mowgod, Assiut University
While diet can support IBD management, with the potential to positively benefit perinatal as well as longer-term health outcomes, little is known about the quality of dietary patterns among pregnant women with IBD , therefore, the objectives of our study are to assess the dietary patterns and diet quality of pregnant women with IBD, and to examine the associations between dietary patterns, diet quality, and dietary guidelines for pregnancy and growth of their offerings

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

Pregnancy is a critical time for the intergenerational transmission of health (. Pregnant women with active inflammatory bowel disease (IBD), a chronic disease characterized by inflammation of the gastrointestinal tract are considered to be at higher risk of poor pregnancy outcomes such as preterm birth, low birthweight or small for gestational age (SGA), spontaneous abortion, and stillbirth, and comprise an increased percentage of Cesarean deliveries compared to women in remission or without IBD. The prevalence of IBD has been increasing worldwide; thus, improving the health of pregnant women with IBD is essential to decreasing their risk for adverse pregnancy outcomes.

A balanced perinatal diet can support optimal health for pregnant women and have a long-term impact on their offspring. Patients with IBD are already prone to nutrition deficiencies due to factors such as restrictive diets, nutrient loss, drug-nutrient interaction, and decreased absorption from the ileum. Furthermore, reduced oral intake and chronic inflammation increases nutrient needs among IBD patients. Two reports have explored the diets of pregnant women in the Norwegian Mother and Child Cohort (MoBa). The first study found that compared to pregnant women without IBD, pregnant women with IBD were less likely to adhere to a traditional Norwegian dietary pattern characterized by a high intake of lean fish or fish products, potatoes, rice porridge, cooked vegetables, and gravy, and were more likely to adhere to a Western dietary pattern with higher intake of foods and beverages rich in sugar and saturated fats. Moreover, pregnant women with IBD who did adhere to the traditional Norwegian diet had lower odds of having an SGA infant. The second study found that pregnant women with IBD consumed a lower proportion of protein from dairy products compared to pregnant women without IBD. In this case, a reduced intake of protein from dairy was associated with a lower risk of having an SGA infant.

Maternal diet during pregnancy has also been linked to the infant microbiome composition, which is critical for the priming of a balanced immune system during early life. Importantly, it was demonstrated that infants born to women with IBD have less diverse microbiomes and higher levels of fecal calprotectin (a biomarker of intestinal inflammation) compared to the infants of women without IBD. Along with emerging reports demonstrating the mediating role of the gut microbiota in the effectiveness of dietary interventions for IBD management, this finding suggests that improving dietary patterns during pregnancy may beneficially modify the microbiome composition, thereby promoting both maternal and infant health. This hypothesis is being explored by the MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) Trial Diet has been increasingly integrated into IBD management, and studies demonstrate the effectiveness of dietary interventions for inducing IBD remission. In adults, the specific carbohydrate diet (SCD); the Mediterranean diet; the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (low FODMAP) diet; and the anti-inflammatory IBD (IBD-AID) diet are among those that have shown efficacy in reducing disease activity and symptoms. Yet, informational resources on nutrition for pregnant women with IBD are sparse. The USDA MyPlate website focuses on a variety of food groups with only broad suggestions of foods and meal plans specific to pregnancy and postpartum needs. The 2014 and 2017 American College of Obstetricians and Gynecologists (ACOG) guideline statements seem focused on nutrients that may be obtained by taking a prenatal vitamin, rather than on whole foods. The 2019 American Gastroenterological Association's Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway report encourages nutrition consultation for specific nutrient deficiency and weight gain patterns in this population, but with few details on compliance to guidelines. In keeping with these publications, pregnant women may hear only general advice from health care providers to take a prenatal vitamin, follow a healthy diet, limit caffeine intake, avoid alcohol and tobacco, and observe caution with seafood. However, while a prenatal vitamin may be recommended in addition to a healthy diet, it cannot supply all the nutrients that are needed to promote healthy and low-risk pregnancies.

Tipo de estudio

De observación

Inscripción (Estimado)

50

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Amira Mohamed Abdelmawgod, MD
  • Número de teléfono: 01012760437
  • Correo electrónico: amiramohmad60@gmail.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra de probabilidad

Población de estudio

  • Patients underwent clinical, laboratory, endoscopic, and/or imaging evaluations as part of routine outpatient monitoring.
  • Laboratory investigations (Complete blood picture, Liver function tests, C-reactive protein and ESR, Fecal calprotectin).
  • The following variables were evaluated: age, sex, BMI [weight (kg)/height (m)²], Calories per day, vitamins intake, method of divert, offsprings evaluation ( weight, height, head circumference, growth velocity, lactation evaluation and vitamins intake), history of IBD-related surgeries, current and prior concomitant medications, disease duration

Descripción

Inclusion Criteria:

  • All pregnant women and documented IBD diagnosis.
  • The diagnosis of IBD was based on the patient's history supported by clinical, endoscopic and histologic documentation

Exclusion Criteria:

  • Inability to provide informed consent
  • HIV/Aids, multi-fetus pregnancy, fetal chromosomal or structural abnormalities
  • intrauterine growth restriction, active infection (including chorioamnionitis or sepsis), renal disease, or a dietary regime that conflicts with the intervention diet.
  • Pregnant IBD patients who had active perianal or extra-intestinal disease or were treated with antibiotic therapy or steroids at recruitment
  • Women scheduled for C-section prior to week 37

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Dietary Patterns and Diet Quality Among Pregnant Women with Inflammatory Bowel Disease and Their Association with Pregnancy Outcomes and Infant Growth
Periodo de tiempo: Data collection: During pregnancy (across trimesters) and follow-up until infant growth assessment (e.g., up to 12-24 months after delivery)
This study aims to evaluate dietary patterns and overall diet quality among pregnant women diagnosed with Inflammatory Bowel Disease. It further seeks to examine the relationship between maternal dietary patterns, adherence to pregnancy dietary guidelines, and their impact on perinatal outcomes as well as infant growth. The findings are expected to provide insights into nutritional gaps and inform dietary recommendations for this specific population.
Data collection: During pregnancy (across trimesters) and follow-up until infant growth assessment (e.g., up to 12-24 months after delivery)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de julio de 2026

Finalización primaria (Estimado)

1 de abril de 2027

Finalización del estudio (Estimado)

1 de abril de 2028

Fechas de registro del estudio

Enviado por primera vez

24 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

24 de abril de 2026

Publicado por primera vez (Actual)

1 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

11 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de mayo de 2026

Última verificación

1 de abril de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 04-2026-300837

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir